Home > Boards > US Listed > Medical - Healthcare > Second Sight Medical Products Inc (EYES)

Notice of Delisting or Failure to Satisfy a

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Big Barnie Member Profile
 
Followed By 2
Posts 893
Boards Moderated 1
Alias Born 07/11/13
160x600 placeholder
Notice of Effectiveness (effect) Edgar (US Regulatory) - 6/15/2021 6:44:06 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/10/2021 1:09:20 PM
UiPath, Campbell among premarket losers' pack Seeking Alpha - 6/9/2021 8:25:44 AM
Second Sight Medical files for $250 million mixed securities shelf offering Seeking Alpha - 6/9/2021 6:55:08 AM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 6/8/2021 5:01:09 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/3/2021 6:04:01 AM
Second Sight Medical Products Announces Results of its 2021 Annual Meeting Business Wire - 6/1/2021 6:00:00 AM
Second Sight Medical trades higher on news of patent win Seeking Alpha - 5/21/2021 12:16:58 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/13/2021 6:03:48 AM
Second Sight Medical Products Announces Year Three NIH Funding of Its Orion Study Business Wire - 5/13/2021 6:00:00 AM
Second Sight Medical reports two-year results of its Orion study Seeking Alpha - 5/12/2021 6:25:26 AM
Second Sight Medical Products Announces Two-Year Results of its Orion Study Business Wire - 5/12/2021 6:00:00 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/30/2021 5:25:08 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 4/29/2021 6:16:20 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 4/27/2021 5:40:31 PM
Amended Annual Report (10-k/a) Edgar (US Regulatory) - 4/27/2021 4:10:30 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 4/22/2021 4:42:52 PM
Second Sight slips 8% on launch of stock offering Seeking Alpha - 4/16/2021 8:34:12 AM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 4/16/2021 6:02:07 AM
Small Company Offering and Sale of Securities Without Registration (d) Edgar (US Regulatory) - 4/7/2021 6:02:22 AM
Second Sight Medical Products Names Dean Baker and Alexandra Larson to its Board of Directors Business Wire - 4/6/2021 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/6/2021 6:29:23 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/5/2021 9:19:25 AM
Second Sight Medical terminates business combination with Pixium Vision Seeking Alpha - 4/3/2021 9:13:41 PM
Second Sight Medical appoints new acting CEO Seeking Alpha - 4/1/2021 1:29:12 PM
Big Barnie   Sunday, 10/04/20 06:21:51 PM
Re: None
Post # of 1174 
Notice of Delisting or Failure to Satisfy a Continued Listing

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard.

Letter from Nasdaq dated October 1, 2020

On October 1, 2020, Second Sight Medical Products, Inc. (the “Company”) received a letter (the “Notice”) from The Nasdaq Stock Market (“Nasdaq”) advising the Company that for 30 consecutive business days preceding the date of the Notice, the bid price of the Company’s common stock had closed below the $1.00 per share minimum required for continued listing on the Nasdaq Capital Market (the “Minimum Bid Price Requirement”) as required by Nasdaq Listing Rules.

The Notice has no effect on the listing of the Company’s common stock at this time, and the Company’s common stock continues to trade on The Nasdaq Capital Market under the symbol “EYES.”

Under Nasdaq Listing Rule 5810(c)(3)(A), if during the 180 calendar day period following the date of the Notice (the “Compliance Period”), the closing bid price of the Company’s common stock is at or above $1.00 for a minimum of 10 consecutive business days, the Company will regain compliance with the Minimum Bid Price Requirement and its common stock will continue to be eligible for listing on the Nasdaq Capital Market absent noncompliance with any other requirement for continued listing.

If the Company does not regain compliance with the Minimum Bid Price Requirement by the end of the Compliance Period, under Nasdaq Listing Rule 5810(c)(3)(A)(ii), if on the last day of the Compliance Period the Company is in compliance with the market value of publicly held shares requirement for continued listing, as well as all other standards for initial listing of its common stock on the Nasdaq Capital Market (other than the bid price requirement), the Company may be eligible for additional time if the Company also provides written notice to Nasdaq of its intention to cure the deficiency during a second compliance period at which point Nasdaq may grant the Company an additional 180 days to regain compliance with the Minimum Bid Price Requirement.

If the Company does not regain compliance with the Minimum Bid Price Requirement by the end of the Compliance Period (or the Compliance Period as may be extended) the Company’s common stock will be subject to delisting.

The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider implementing available options to regain compliance with the Minimum Bid Price Requirement under the Nasdaq Listing Rules.



A list of all non-compliant Nasdaq companies and the reason(s) for such non-compliance is posted on Nasdaq’s website at listingcenter.nasdaq.com. The Company will be included in this list commencing five business days from the notification date.



Date: October 2, 2020

SECOND SIGHT MEDICAL PRODUCTS, INC.

Matthew Pfeffer



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences